Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

NCT04362813 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

454

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Interventions

DRUG: Canakinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals